ClinicalTrials.gg
CompletedNCT06569056Updated Sep 30, 2026

A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

A Phase 3 interventional study of HRS-8427 and Imipenem and Cilastatin Sodium in Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP), sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Sep 30, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
579
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of HRS-8427 in patients with complicated urinary tract infection, including acute pyelonephritis.

02

Conditions studied

  • Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
03

In context

Pyelonephritis

79 studies on the registry are indexed under Pyelonephritis; 12 are open to participants now.

This study's enrollment of 579 is above the median of 175 across 62 interventional studies indexed under Pyelonephritis.

Browse Pyelonephritis studies →

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written before the study, fully understand the study and be able to complete the study according to the protocol;
  2. Male and female, ≥18 years;
  3. Judged by the investigator, clinical diagnosis with cUTI or AP, expectation that the patients will require hospitalization and initial treatment with intravenous antibiotics;
  4. Urine specimen with evidence of pyuria;
  5. Have urine culture specimen obtained within 48 hours prior to randomization;
  6. 48 hours before random, allowing a short course of antimicrobial drug treatment is less than 24 hours (random rate ≤25%)
  7. Women of must have a negative serum pregnancy test before first dose, must be non-lactating. Fertile female subjects or male subjects whose partner is a fertile female agree to use highly effective form of , with no plan of birth, sperm/ovum donation from the time of signed ICF till 14 days after end of treatment.

Exclusion criteria

Exclusion Criteria:

  1. History of significant or allergic reaction to any β-lactam, or any β-lactamase inhibitors;
  2. Known history of immune deficiency disease or receive immunocompromising treatment;
  3. Severe cardiovascular and cerebrovascular diseases with clinical significance and unstable condition or uncontrolled;
  4. Known or suspected central nervous system disorder or other factors that may predispose to seizures or lower the seizures onset threshold;
  5. Presence of any known or suspected disease or condition that, in the opinion of the Investigator, may confound the assessment of efficacy;
  6. Uncomplicated lower urinary tract infection;
  7. Suspected or confirmed urinary tract symptoms caused by acute/chronic prostatitis, orchitis, epididymitis or sexually transmitted diseases as determined by medical history and/or physical examination;
  8. Patients received cancer treatment within 4 weeks before randomization or planned treatment during the study period;
  9. Systemic antimicrobial therapy other than the drug need to be used during the study period, with the exception of topical or single oral dose of antifungal treatment
  10. Urinary tract surgery prior to 7 days before randomization or surgery planned during the study period;
  11. Indwelling catheter or urinary apparatus, the researchers determine drug treatment period cannot be removed;
  12. Receipt of potentially effective systemic antibacterial therapy for a continuous duration of ≥24 hours during the previous 48 hours prior to the randomization;
  13. History of pelvis or urinary tract trauma prior to the randomization;
  14. Patients had severe trauma or received major surgery prior to the randomization;
  15. Impairment of renal function with estimated or \<15 mL/min ;
  16. Laboratory abnormalities in baseline specimens obtained at screening;
  17. A interval prolongation at screening or abnormalities with clinical significance and may cause obvious safety risk to the subjects;
  18. Known urine culture with at least one Gram-Negative uropathogen at ≥105 colony-forming units(CFU)/mL unsusceptible to Imipenem and Cilastatin Sodium, or only identify Gram-positive uropathogen, or confirmed fungal urinary tract infection with ≥103CFU/mL;
  19. Likely to require the use of antibiotic drug prevention after treatment;
  20. Suspected of sepsis, producing life-threatening organ dysfunction;
  21. Estimated survival within 6 weeks or rapidly progressive or end stage disease with high mortality rate;
  22. Drug abuse prior to the randomization;
  23. Participated in a previous clinical study related to HRS-8427 and used HRS-8427 or have participated in another clinical study within 4 weeks before randomization and used a study drug containing the active ingredient;
  24. Judgment of the Investigator, other reasons unsuitable for study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
579 participants (actual)

Study arms

  • Experimental
    HRS-8427; Imipenem and Cilastatin Sodium placebo

    Drug: HRS-8427 · Drug: Imipenem and Cilastatin Sodium placebo

  • Active comparator
    Imipenem and Cilastatin Sodium; HRS-8427 placebo

    Drug: Imipenem and Cilastatin Sodium · Drug: HRS-8427 placebo

Interventions

  • Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

  • DrugImipenem and Cilastatin Sodium

    Drug pages: Imipenem · Cilastatin

    Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

  • DrugHRS-8427 placebo

    Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

  • DrugImipenem and Cilastatin Sodium placebo

    Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure (TOC)

    Time frame: Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21)

Secondary outcomes

  1. Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment(EA)、End of Treatment(EOT)and Late Follow-Up (LFU)

    Time frame: EA : Day 4、EOT: Day 7 to Day 14、LFU:Day 21 to Day 28

  2. Percentage of Participants With Microbiological Eradication at EA 、EOT、TOC and LFU

    Time frame: EA : Day 4、EOT: Day 7 to Day 14、TOC:Day 14 to Day 21、LFU:Day 21 to Day 28

  3. Percentage of Participants With Microbiological Eradication at EA 、EOT、TOC and LFU Per Uropathogen

    Time frame: EA : Day 4、EOT: Day 7 to Day 14、TOC:Day 14 to Day 21、LFU:Day 21 to Day 28

  4. Percentage of Participants With Clinical Response at EA 、EOT、TOC and LFU

    Time frame: EA : Day 4、EOT: Day 7 to Day 14、TOC:Day 14 to Day 21、LFU:Day 21 to Day 28

  5. Percentage of Participants With Clinical Response at EA 、EOT、TOC and LFU Per Uropathogen

    Time frame: EA : Day 4、EOT: Day 7 to Day 14、TOC:Day 14 to Day 21、LFU:Day 21 to Day 28

  6. Number of Participants With Adverse Events

    Time frame: Day 21 to Day 28

07

Study locations

1 site
  • Shanghai Huashan Hospital
    Shanghai, Shanghai Municipality 200040, China
08

References and documents

Publications

  • Yin T, Qu B, Zhang Q, Xu S, Wu Y, Jiang H, Huang Y, Hu W. Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjects. Antimicrob Agents Chemother. 2026 Apr;70(4):e0069425. doi: 10.1128/aac.00694-25. Epub 2026 Mar 3. PubMed 41773934 ↗
  • Wu Y, Han Q, Yang H, Xue J, Wang L, Mao X, Yin T, Jiang H, Xu S, Huang Y, Wang T, He Y, Luo Y, Chen W, Zhang J. Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of HRS-8427, a siderophore cephalosporin for Gram-negative bacterial infections. Antimicrob Agents Chemother. 2026 Feb 4;70(2):e0109525. doi: 10.1128/aac.01095-25. Epub 2026 Jan 13. PubMed 41528248 ↗
  • Cao Y, Huang Y, Xie J, Wu Q, Yang S, Yang X, Huang J, Liu J, Meng J, Yang G. Intrapulmonary penetration and pharmacokinetics of siderophore cephalosporin HRS-8427 injection in Chinese healthy subjects. Antimicrob Agents Chemother. 2025 Dec 10;69(12):e0070225. doi: 10.1128/aac.00702-25. Epub 2025 Nov 6. PubMed 41196282 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2024 to primary completion in Sep 2026, 23 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Nov 2026 → Sep 2026 and completion Nov 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2024
First posted
Aug 23, 2024
StartActual
Sep 25, 2024
Primary completionActual
Sep 1, 2026was Nov 2026
CompletionActual
Sep 1, 2026was Nov 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 30, 2026
Primary completion
Nov 2026→Sep 1, 2026 (actual)
Sep 30, 2026
Study completion
Nov 2026→Sep 1, 2026 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Active, not recruiting→Completed
    Primary completion Nov 2026→Sep 1, 2026 (now actual)
    Study completion Nov 2026→Sep 1, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06569056
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Sep 25, 2024
Primary completion
Sep 1, 2026
Completion
Sep 1, 2026
Last update
Sep 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-8427

Start the discussion